Czechia· CZ-0168973
ZELBORAF
A vemurafenib product containing vemurafenib and hypromellose acetate succinate, registered in Czechia by Roche Registration GmbH, Grenzach-Wyhlen. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Vemurafenib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EC01 (vemurafenib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Vemurafenib · ATC L01EC01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vemurafenib costs, country by country.
Normalised to the WHO defined daily dose (1.92 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vemurafenib · price per daily dose (1.92 g)
USD · FX 28 Sept 2026
- CH Switzerland$263.61
The record
At a glance
SÚKL (Czech Republic)- Active substance
- VEMURAFENIB AND HYPROMELLOSE ACETATE SUCCINATE
- Manufacturer
- Roche Registration GmbH, Grenzach-Wyhlen
- Country
- Czechia (CZ)
- ATC code
- L01EC01
- ATC class
- Vemurafenib
- Defined daily dose
- 1.92 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl016897356X1CZK 36668.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
661 interactions on record for vemurafenib.
Graded by severity as the source publishes them — 264 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vemurafenib · interactions on record
661 records
- 264 severe
- 377 moderate
- 20 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EC01
Vemurafenib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc30e696-52ba-49f1-9558-b8b7ce3d8a96 GET /v1/drugs/dc30e696-52ba-49f1-9558-b8b7ce3d8a96?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "240MG",
"pack_size": "56X1",
"substance": "VEMURAFENIB AND HYPROMELLOSE ACETATE SUCCINATE",
"cz_kod_sukl": "0168973",
"product_type": "CH",
"substance_codes": "20151",
"registration_state": "R",
"registration_number": "EU/1/12/751/001"
}See everything about vemurafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.